TrialBlood cancer journal2024

Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial.

Arleigh McCurdy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.